Isolated leptomeningeal relapses in high-risk neuroblastoma
Authors:
- A. N. TurchinaATA. N. Turchina
- D. Yu. KachanovDKD. Yu. Kachanov
- N. A. AndreevaNAN. A. Andreeva
- D. T. UtalievaDUD. T. Utalieva
- R. A. MoiseenkoRMR. A. Moiseenko
- I. V. SidorovISI. V. Sidorov
- D. M. KonovalovDKD. M. Konovalov
- M. E. DubrovinaMDM. E. Dubrovina
- A. A. GvozdevAGA. A. Gvozdev
- T. V. ShamanskayaTST. V. Shamanskaya
Open Access
- 1 August 2025
- journal article
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (2) , 96-106
Abstract
Background. Neuroblastoma (NB) is the most common extracranial solid malignant tumor of childhood, about 50 % of patients with NB are stratified into a high-risk (HR) group at the time of diagnosis. Despite the multimodal approach to therapy, half of the patients develop relapse of the disease, affecting mostly bones and bone marrow. Relapses with localization in the central nervous system (CNS) are extremely rare and are predominantly parenchymal in nature. Isolated leptomeningial involvement at relapse is an incredibly rare (0.6 % of all relapses), but is characterized by extremely aggressive manifestation and associated with unfavorable prognosis.Materials and methods. A description of three clinical cases of CNS relapses with isolated leptomeningeal lesions in patients with HR NB treated at Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia.Results. The study included 3 patients with isolated leptomeningeal relapse of NB. The age at the time of the initial diagnosis was 23, 36, and 80 months. Initially, the patients were stratified into a HR group according to the GPOH NB-2004 protocol. Amplification in the MYCN gene was detected in two patients, gain MYCN in one; deletion of the 1p chromosomal region was also detected in two patients, and deletion of the 11q chromosomal region in one patient. Two patients had a mutation in the ALK gene: in one case, the mutation was found in the primary tumor tissue, in the other – in the relapse tumor tissue. The time from the initial diagnosis to the detection of leptomeningeal recurrence of the disease was 5, 15 and 16 months. In two cases, CNS relapse debuted with the appearance of clinical symptoms, in one case it was detected during a follow-up examination. All patients received anti-relapse therapy with drugs that penetrate the blood-brain barrier, two received molecular-directed therapy with ALK inhibitors, and only one patient received craniospinal irradiation and intrathecal administration of a chemotherapy drug.Two patients died as the disease progressed. One patient is alive at the time of the publication without disease progression, the follow-up time is 9 months from the diagnosis of relapse.Conclusions. Leptomenigial CNS lesion in relapse NB may be characterized by a non-specific clinical presentation requiring a differential diagnosis with the toxicity of therapy. Comprehensive therapeutic approach with chemotherapy, radiation therapy, and intrathecal administration of drugs is needed to improve the long-term survival of this subgroup of patients.Keywords
This publication has 18 references indexed in Scilit:
- Neoplastic meningitis in solid tumours: updated review of diagnosis, prognosis, therapeutic management, and future directionsNeurología (English Edition), 2022
- Isolated central nervous system relapses in patients with high-risk neuroblastoma -clinical presentation and prognosis: experience of the Polish Paediatric Solid Tumours Study GroupBMC Cancer, 2022
- Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experienceEuropean Journal of Cancer, 2021
- Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HRAnnals of Oncology, 2020
- High-Risk Neuroblastoma and Current Protocols2019
- Surgical Treatment for Leptomeningeal DiseaseCancer Control, 2017
- Treatment and outcomes of patients with relapsed, high‐risk neuroblastoma: Results of German trialsPediatric Blood & Cancer, 2010
- Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastomaJournal of Neuro-Oncology, 2009
- Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failurePediatric Blood & Cancer, 2007
- Brain metastasis in children with sarcoma, neuroblastoma, and Wilms’ tumorInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2003